glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
The Canadian Penning Trap Mass Spectrometer (CPT) is one of the major pieces of experimental equipment that is installed on the ATLAS superconducting heavy-ion linac facility at the Physics Division of the Argonne National Laboratory. It was developed and operated by physicist Guy Savard and a collaboration of other scientists at Argonne, the University of Manitoba, McGill University, Texas A&M University and the State University of New York.
Half-Life 2 has an aggregate score of 96/100 on Metacritic based on 81 reviews. Sources such as 1UP, GameSpy, The Cincinnati Enquirer, The New York Times, and VideoGamer.com gave it perfect scores, and others, such as PC Gamer, IGN, GamesRadar, and Eurogamer, gave near-perfect scores. It was the fifth game to receive ten out of ten from Edge. Critics praised the graphics, physics, story and gameplay. Maximum PC awarded Half-Life 2 11 on their rating scale which normally peaks at 10, calling it "the best game ever made". In the United States, Half-Life 2's PC version sold 680,000 copies and had earned $34.3 million by August 2006. It was the country's 17th best-selling PC game between January 2000 and August 2006. It received a "Platinum" sales award from the Entertainment and Leisure Software Publishers Association (ELSPA), indicating sales of at least 300,000 copies in the United Kingdom. Forbes reported on February 9, 2011, that it had sold 12 million copies worldwide. In a review of The Orange Box, IGN stated that although Half-Life 2 has already been released through other media, the game itself is still enjoyable on a console. They also noted that the physics of Half-Life 2 are impressive despite it being a console game. However, it was noted that the graphics on the Xbox 360 version of Half-Life 2 were not as impressive as when it was released on the PC. GameSpot identified framerate problems on PlayStation 3 version.
To perform a selective separation, the distribution ratio of the solute to be extracted must be greater than one, whereas that belonging to the solutes which remain in the aqueous feed must be lower than one. This always yields a separation factor SF > 1. Generally, the effects of acidity and temperature on distribution ratios and the separation factor are investigated because the main species with actinides and lanthanides could be prone to decomplexation upon increasing acidity due to protonation of the ligand or due to increasing temperature. The thermodynamic effects are usually investigated by performing extraction tests at increasing temperature. Furthermore, thermodynamics studies can assess the several alkyl chains of a ligand on its complexation properties towards minor actinides than lanthanides. The extraction processes are based on the complexation of metal ions with lipophilic or hydrophilic ligands. The extracting agent forms a coordination complex with the metal ion as a product of a Lewis acid-base reaction. Ligands are named bases (donors) and contain at least one electron lone pair to donate to metal ions named acids (acceptors). Metal cations in the aqueous feed raffinate are generally solvated by coordinating water molecules through the donor oxygen atoms to form aquo ions
=== First Nations relations === In March 2021, Ford publicly accused MPP Sol Mamakwa of "jumping the line" to receive his second dose of a COVID-19 vaccine, despite being eligible to receive it. Mamakwa went to his riding to receive the vaccine as an attempt to prevent vaccine hesitancy amongst his constituents. On Thursday, March 11, 2021, Ford apologised for his remark and later said he "got a little personal" when throwing the accusation at Mamakwa. Mamakwa did not say that he accepted Ford's apology but stated that he appreciated the call from Ford. In September 2021, an Ontario judge issued an injunction on mining in Wiisinin Zaahgi'igan (an area sacred to the Ginoogaming First Nation peoples). The judge ruled that the Ontario government did not consult with the Ginoogaming as is their constitutional duty. Ford's 2024 Reducing Gridlock, Saving you Time Act removed the requirement for future Indigenous consultation for the upcoming Highway 413 in a possible contravention of Ontario's Environmental Assessment Act. In addition, the Indigenous consultation period for the bill was only 30 days, decried by the regional chief as 'too short'. Many Indigenous and environmental advocacy groups opposed his government's Protecting Ontario by Unleashing Our Economy Act, or Bill 5, which gives Ford's cabinet the ability to create special economic zones and exempt companies or projects from having to comply with any provincial law, provincial regulation or municipal bylaw. Ford also apologized for saying that First Nations "keep coming hat in hand" for government money in June 2025.
Sources: en.wikipedia.org
The COVID-19 pandemic in North Korea was part of a global pandemic of coronavirus disease 2019 (COVID-19), a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). North Korea confirmed its first case on 8 May 2022. North Korea is a secretive and diplomatically isolated country in East Asia. Its weak healthcare system and impoverished population led to concerns over the country's vulnerability to an outbreak, though its cold chain vaccination program had proven capable in prior pandemics. With a totalitarian political system, little information on the pandemic's impacts on North Korea has been available to international observers. In January 2020, the North Korean government began taking extensive measures to protect itself from the initial COVID-19 outbreak, including the establishment of quarantine facilities, and strict travel restrictions. In March and April 2020, the Asia Times and 38 North reported that these measures seemed largely successful. Before May 2022, the government of North Korea had not reported any confirmed cases of COVID-19, although some foreign analysts believed that the virus had spread there by March 2020. Daily NK, a South Korean dissident-run news website, said that about 180 soldiers had possibly died from COVID-19 symptoms in January and February 2020. In July 2020, a single suspected case in Kaesong prompted a three-week lockdown. By 2021, there were increasing reports that the isolation imposed to avoid the pandemic was having a major impact on the economy.
Reddy's path into new drug discovery involved targeting specialty generics products in western markets to create a foundation for drug discovery. Development of specialty generics was an important step for the company's growing interest in the development of new chemical entities. The elements involved in creating a specialty generic, such as innovation in the laboratory, developing the compound, and sending the sales team to the market, are also stages in the development of a new specialty drug. Starting with specialty generics allowed the company to gain experience with those steps before moving on to creating brand-new drugs. Reddy's invested heavily in establishing R&D labs and is the only Indian company to have significant R&D being undertaken overseas. Dr. Reddy's Research Foundation was established in 1992 and in order to do research in the area of new drug discovery. At first, the foundation's drug research strategy revolved around searching for analogues. Focus has since changed to innovative R&D, hiring new scientists, especially Indian students studying abroad on doctoral and post-doctoral courses. In 2000, the Foundation set up an American laboratory in Atlanta, dedicated to discovery and design of novel therapeutics. The laboratory is called Reddy US Therapeutics Inc (RUSTI) and its main aim is the discovery of next-generation drugs using genomics and proteomics. Reddy's research thrust focused on large niche areas in western markets – anti-cancer, anti-diabetes, cardiovascular and anti-infection drugs.
==== TP0453 ==== TP0453 is a 287 amino acid protein associated with the inner membrane of the microbe's outer membrane. This protein lacks the extensive beta sheet structure that is characteristic of other membrane proteins, and does not traverse the outer membrane. This protein's function has been hypothesized to be involved with control of nutrient uptake.
A similar method called atmospheric solids analysis probe (ASAP) uses the heated gas from ESI or APCI probes to vaporize sample placed on a melting point tube inserted into an ESI/APCI source. Ionization is by APCI. Laser-based ambient ionization is a two-step process in which a pulsed laser is used to desorb or ablate material from a sample and the plume of material interacts with an electrospray or plasma to create ions. Electrospray-assisted laser desorption/ionization (ELDI) uses a 337 nm UV laser or 3 μm infrared laser to desorb material into an electrospray source. Matrix-assisted laser desorption electrospray ionization (MALDESI) is an atmospheric pressure ionization source for generation of multiply charged ions. An ultraviolet or infrared laser is directed onto a solid or liquid sample containing the analyte of interest and matrix desorbing neutral analyte molecules that are ionized by interaction with electrosprayed solvent droplets generating multiply charged ions. Laser ablation electrospray ionization (LAESI) is an ambient ionization method for mass spectrometry that combines laser ablation from a mid-infrared (mid-IR) laser with a secondary electrospray ionization (ESI) process.
== Adverse effects == Rarely allergic reactions may occur (from dermal or mucosal symptoms to anaphylactic shock). At overdosing a toxical reaction arises - excitation, agitation, dishevelment, visual defects, buzzing in ears, muscle thrill to tremor, in more severe cases somnolence, hyporeflexia, breathing defects to apnea, convulsions.
Sources: en.wikipedia.org
== Pharmacology == Dimethyl fumarate is metabolized to monomethyl fumarate (MMF) prior to entering systemic distribution. Dimethyl fumarate has been described a prodrug. Dimethyl fumarate is a precursor of monomethyl fumarate. Other prodrugs that metabolize to monomethyl fumarate have been developed to treat relapse-remitting multiple sclerosis, including diroximel fumarate which was approved by the FDA in October 2019. The precise mechanism of action of dimethyl fumarate is not clear. Dimethyl fumarate and monomethyl fumarate can activate the transcription factor (Nuclear factor erythroid-derived 2)-related factor 2 (Nrf2) pathway and monomethyl fumarate has been identified as a nicotinic acid receptor agonist in vitro. In mice that lack Nrf2 expression, however, dimethyl fumarate is still able to modulate the immune system, which indicates that Nrf2 is not required for its immunomodulatory action. For psoriasis, the mechanism of action is believed to be due to the interaction of monomethyl fumarate and the intracellular reduced glutathione of cells directly involved in the pathogenesis of psoriasis. The interaction with glutathione leads to the inhibition of nuclear translocation and the transcriptional activity of the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Dimethyl fumarate and monomethyl fumarate have been shown to reduce the expression of micro-RNA-21, which is essential for the production of pathogenic cells in multiple sclerosis and psoriasis.
Mister Donut has an orange and white logo in the likeness of a moustachioed chef. More recently, the chain developed a set of mascot characters based on its donuts. One character, "Pon de Lion" (ポン・デ・ライオン, Pon De Raion), a lion with a mane shaped like its "pon de ring" (ポン・デ・リング, Pon De Ringu) donut line, is used in Japan. In El Salvador, the mascots are five anthropomorphic doughnuts and a rooster that is used for the breakfast menu. The company uses the same logo as Japan, and the slogan is "La gran variedad" (The great variety).
== Further reading == Reilly, Bernard F. (1988). "The Reconstitution of León-Castilla". The Kingdom of León-Castilla under King Alfonso VI, 1065–1109. Princeton: Princeton University Press. pp. 3–13. ... the hilltop, fortress city of Coimbra fell, after a six-month siege, on July 25, 1064.
==== Inhalation and smoking ==== Results from epidemiological studies indicate that the risk of lung cancer increases with exposure to residential radon. One well known potential source of error in these studies is smoking, which is the main risk factor for lung cancer. In the US, cigarette smoking is estimated to cause 80% to 90% of all lung cancers. Radon, like other known or suspected external risk factors for lung cancer, is a threat for smokers and former smokers. According to the EPA, the risk of lung cancer for smokers is significantly higher when they are exposed to radon due to the synergistic effects of radon with smoking. For this population, about 62 people in a total of 1,000 will die of lung cancer, compared to 7 people in a total of 1,000 for people who have never smoked. A 2005 review article by Darby and colleagues analyzing 13 different case studies across Europe stated: "It is not appropriate to talk simply of a risk from radon in homes. The risk is from smoking, compounded by a synergistic effect of radon for smokers. Without smoking, the effect seems to be so small as to be insignificant." According to Darby, there is a difference in risk for the histological subtypes of lung cancer and radon exposure. Small-cell lung carcinoma, which has a high correlation with smoking, has a higher risk after radon exposure. For other histological subtypes, such as adenocarcinoma, the type that primarily affects non-smokers, the risk from radon appears to be lower.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。